Ovid Therapeutics Inc. (NASDAQ:OVID) went down by -3.44% during the previous trading session, and it is maintaining the win ahead of Tuesday’s trading session. The share price of the Biotechnology giant went up by $5.47 to trade ended Tuesday trading at $5.67. This is down from the $5.67 price recorded on Monday’s trading session. Its performance from the start of the year has also been positive, with OVID up by 31.93% year-to-date.
Ovid Therapeutics Inc. (OVID) started the day trading at $5.74 and recorded an intraday high of $5.76. It also recorded an intraday low of $5.35 during Tuesday’s trading session. Ovid Therapeutics Inc. is a very active stock that recorded a trading volume that is more than 13.4% of the average daily trading volume on Tuesday. The stock’s trading volume on Tuesday was 970891, which is more than 13.4 of the total average daily trading volume of 840.83K.
Ovid Therapeutics Inc. (NASDAQ:OVID) 2020 Performance Impressive
The increase in OVID’s stock price on Tuesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of OVID currently stands at $7.21, which is higher than the current trading price of the stock by 24.13%. However, OVID’s current trading price is -227.54% lower than the 52-week low price of $1.67. In terms of trading volume, Ovid Therapeutics Inc. currently experienced healthy participation during the last trading session. 970891 shares of Ovid Therapeutics Inc. were traded on the stock exchange on Tuesday, which is more than 13.4% of the 840.83K average trading volume of the stock.
The performance of the stock has been positive over the past year. OVID’s performance over the past one year has seen it surge by 223.96%, while the stock has gone up by 35.86% in the last six months. The quarterly performance of OVID currently stands at 130.04%, and it is up by 33.21% in the last month. The only positive figure was from the weekly performance, which currently reads 2.15%. At the time of writing OVID’s report, the company has a total market cap of $275.83M, making it one of the largest publicly-traded companies in the world.Ovid Therapeutics Inc. also has over 65 employees all over the world.
OVID Insider Activities
For Ovid Therapeutics Inc., insiders hold 29.20% of all company shares. The insider transactions over the past six months are down by 0.00%. During that period, insiders bought 0 shares in 0 transactions. In that same period, insiders sold 0 of their shares in 0 transactions. After these transactions, insiders at Ovid Therapeutics Inc. now hold 22.46M shares, which is over 33.28% of the total company stocks. Institutional investors currently hold a large chunk of the OVID shares, as they control 41.03% of the company’s total stock.
OVID Fundamental Analysis
For Ovid Therapeutics Inc., the stock’s diluted earnings per share (EPS) stands at -1.48. In the coming year, analysts expect the EPS to be -1.31.
At the moment, Ovid Therapeutics Inc.’s Total Debt to Equity ratio stands at 0.00, and they have a long-term Debt to Equity ratio of 0.00.
OVID Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of OVID currently stands at 3.04%, while the SMA50 is 30.01%. The biggest one is the SMA200, which is currently reading 60.84% ahead of Tuesday’s trading session. The Relative Strength Index of this stock is 56.77.
